Fezolinetant is an oral, once-daily, nonhormonal drug that blocks a specific brain receptor (an NK3 receptor antagonist), FDA-approved in 2023 for moderate to severe hot flashes and night sweats due to menopause.
In trials it meaningfully reduced hot flash frequency beyond placebo, working within about a week and sustained through a year, with no signal of harm to the uterine lining or bone density. In December 2024 the FDA added a boxed warning after a rare postmarketing case of serious liver injury, so it now requires liver blood tests before starting and at scheduled intervals afterward.
One reading treats the safety signals as manageable label matters, given clean trial data and a monitoring-based response. The other reading, raised as an explicitly unproven hypothesis by one physician, urges respecting the unknowns of a first-in-class CNS-acting drug that has only 52 weeks of trial data in about 2,000 people.
What the research shows, and which source each finding rests on
In the SKYLIGHT 1 phase 3 trial (n approximately 525), versus placebo, fezolinetant 45 mg reduced daily vasomotor symptom frequency by an additional 2.07 episodes at week 4 and 2.55 at week 12 (both p < 0.001), with onset within 1 week and effect maintained through 52 weeks
SKYLIGHT 4, a 52-week safety study (n = 1,830), found no endometrial safety signal, no bone density change, and liver enzyme elevations more than 3 times the upper limit of normal in 8/590 (30 mg) and 12/589 (45 mg) participants versus 6/583 on placebo, with no cases matching the pattern of severe drug-induced liver injury
On 16 December 2024 the FDA added a boxed warning for rare but serious liver injury, based on a postmarketing case of hepatocellular injury with jaundice within 40 days of starting the drug that resolved after discontinuation; required monitoring is baseline liver labs, then monthly for the first 2 months, then at months 3, 6, and 9, with immediate discontinuation for symptoms of liver injury
Where the real disagreement is
Each position is shown with its own sources. A position listed here is not necessarily the accepted view.
The signals are manageable label matters
The trial evidence base and the FDA's monitoring-based regulatory response
The 52-week safety trial found transaminase elevations without any case matching the pattern of severe drug-induced liver injury, and the FDA's boxed warning rests on a rare postmarketing case that is now managed with a defined monitoring schedule, with the injury resolving on discontinuation.
Respect the unknowns of a first-in-class CNS drug
Felice Gersh, raising a theoretical hypothesis
Publicly discusses a 2026 review raising theoretical concerns tied to the drug's receptor mechanism, while explicitly stating none of this is proven and cautioning against alarm; also notes the relevant receptor exists outside the hypothalamus, including in the gut and liver.
What would settle it: Accumulating pharmacovigilance (adverse event reporting) data, registry studies, and the mandated postmarketing surveillance; for any theoretical longer-term hypothesis, long-term cohort data.
What is really going on here
- If I start Veozah, what is the liver monitoring schedule? Baseline labs, then monthly for 2 months, then months 3, 6, and 9, with stopping for jaundice, dark urine, itching, nausea, or unusual fatigue.
Questions for your doctor
- What is the liver monitoring schedule, and who will track it, me or the clinic?
- What symptoms of liver injury should prompt me to stop immediately and call?
- Am I a candidate for fezolinetant, or would hormone therapy or another nonhormonal option fit me better?
- How will we know within the first few weeks whether it's working for me?
Questions with no answer yet
Does the receptor this drug blocks have effects outside the brain, since it is also found in the gut and liver, that could explain the rare liver injury cases, or is that connection purely theoretical?
Not directly studied yetNo research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.
What is known: One physician has raised this as an explicitly unproven, theoretical hypothesis in public discussion, noting the receptor's presence outside the hypothalamus in the gut and liver, but no mechanistic study has tested whether that receptor location explains the rare postmarketing liver cases.
What would test it: Mechanistic and pharmacovigilance research specifically investigating whether the drug's activity in gut or liver tissue relates to the reported liver injury cases.
Is a raised theoretical concern about reduced signaling of an anti-metastatic peptide from blocking this pathway a real long-term risk, or a hypothesis-level signal that will not replicate in larger pharmacovigilance data?
Not directly studied yetNo research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.
What is known: This concern was raised in a review discussing possible effects on an anti-metastatic peptide and compensatory receptor activation, explicitly stated by the person raising it as unproven, since no clinical signal for this has appeared in trials to date.
What would test it: Long-term pharmacovigilance and registry data as the drug accumulates more years of real-world use.
Would 52 weeks of safety data in a much larger population than the roughly 2,000 women already studied still show no severe liver injury cases, or does the true rate only become visible at a larger scale, as the postmarketing case suggests?
Partly studiedWhat is known: The pivotal 52-week safety trial found transaminase elevations without any severe injury case, yet a rare postmarketing case did occur once the drug reached a much larger real-world population, which is exactly the kind of rare signal a trial of that size is underpowered to detect.
What would test it: Continued accumulation of postmarketing adverse-event data and registry studies at a larger scale than the pivotal trials.
Sources
- 1.Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study.Lederman S et al., Lancet 2023 · Randomised trial
- 2.Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause: A Randomized Controlled Trial.Neal-Perry G et al., Obstet Gynecol 2023 · Randomised trial
- 3.FDA Drug Safety Communication, 16 December 2024Review, opinion or mechanism
The letter grades the type of study behind a claim, not the answer itself.
This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.
You are not imagining it
In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.
Start Free MappingRelated questions
- How long do hot flashes actually last?
- What actually causes a hot flash in my body?
- Are my hot flashes just uncomfortable, or could they be a warning sign about my heart or brain health?
- What is elinzanetant (Lynkuet) and how is it different from fezolinetant?
- Are the new non-hormonal drugs (fezolinetant, elinzanetant) as good as hormone therapy for hot flashes?
- How do I know if a hot flash treatment actually works, versus me just wanting it to work?
- Back to topic: Hot flashes and their treatments